Interim report
Page 1
Quarterly Statement 9M 2026 for the period from October 1 , 2025 to June 30 , 2026 SCHOTT PHARMA
Page 2
2 10 ml cartridge cartriQ® Large Volume Contents Financial factsheet 3 Business performance and key financial indicators 4 Report on changed forecasts 8 Consolidated statement of income 9 Consolidated statement of financial position 10 Consolidated statement of cash flows 12 Supplementary information 14
Page 3
3 Financial factsheet 9M 2026 October 1, 2025 – June 30, 2026 SCHOTT Pharma Revenue bridge (in EUR m) Revenue by region (in EUR m) Results of operations (in EUR m) 9M 2026 9M 2025 ∆ in % Revenue 769.8 739.2 +4.1% Share of high-value solutions (HVS) 57% 57% - EBITDA 205.3 213.3 -3.8% EBITDA margin 26.7% 28.9% - EBIT 139.7 156.0 -10.4% EBIT margin 18.2% 21.1% - Financial result -6.2 -9.6 -35.6% Income tax expenses -30.2 -32.7 -7.8% Profit for the period 103.4 113.7 -9.0% Earnings per share (in EUR) 0.68 0.75 -9.3% Financial position (in EUR m) 9M 2026 9M 2025 Cash flows from operating activities 140.7 127.7 Cash flows from ongoing investing activities -81.8 -88.2 Free cash flow 58.9 39.6 Net assets (in EUR m) Jun. 30, 2026 Sep. 30, 2025 Working capital 245.4 199.3 Working capital in % of revenue 21.8% 20.2% Equity ratio 58.9% 55.9% Net debt 106.0 122.2 Employees Jun. 30, 2026 Sep. 30, 2025 Headcount (as of the reporting date) 5,002 4,811 Drug Containment Solutions (DCS) Revenue bridge (in EUR m) Results of operations (in EUR m) 9M 2026 9M 2025 ∆ in % Revenue 445.4 413.9 +7.6% EBITDA 109.7 99.6 +10.1% EBITDA margin 24.6% 24.1% - EBIT 80.0 72.1 +11.0% EBIT margin 18.0% 17.4% - Drug Delivery Systems (DDS) Revenue bridge (in EUR m) Results of operations (in EUR m) 9M 2026 9M 2025 ∆ in % Revenue 325.1 325.8 -0.2% EBITDA 95.7 114.4 -16.3% EBITDA margin 29.5% 35.1% - EBIT 60.5 85.2 -28.9% EBIT margin 18.6% 26.1% - 739.2 +32.3 -1.7 769.8 9M 2025 Organic growth FX 9M 2026 385.1 434.0 127.6 121.7 161.3 145.8 65.3 68.4 +12.7% -4.6% -9.6% +4.8% 9M 2025 9M 2026 ∆ in % EMEA APAC North America South America 413.9 +37.9 -6.4 445.4 9M 2025 Organic growth FX 9M 2026 325.8 -5.4 +4.7 325.1 9M 2025 Organic growth FX 9M 2026 +4.4% -0.2% +4.1% -1.7% +1.5% -0.2% +9.2% -1.6% +7.6%
Page 4
SCHOTT Pharma Quarterly Statement as of June 30, 2026 Business performance and key financial indicators 4 Business performance and key financial indicators Preliminary remarks The SCHOTT Pharma Group ( “SCHOTT Pharma”) financial year begins on October 1 and ends on September 30 of the following year. 9M 2026 (previous year: 9M 2025) covers the period from October 1, 2025 to June 30, 2026 (previous year: October 1, 2024 to June 30, 2025). Q3 2026 (previous year: Q3 2025) therefore relates to the period from April 1, 2026 to June 30, 2026 (previous year: April 1, 2025 to June 30, 2025). Results of operations SCHOTT Pharma generated revenue of EUR 769.8m in the first nine months of the financial year 2026, a year-on- year increase of 4.1%, and constant currency revenue growth of 4.4%. This growth was largely driven by the continued buoyant demand for high-value solutions (HVS) and rising demand for core products in the Drug Containment Solutions segment (DCS). The HVS revenue share was 57%, matching the level seen in the financial year 2025. Revenue performance by segment Change in % (in EUR m) 9M 2026 9M 20251 Reported Constant currencies Drug Containment Solutions (DCS) 445.4 413.9 +7.6% +9.2% Drug Delivery Systems (DDS) 325.1 325.8 -0.2% -1.7% Consolidation/reconciliation -0.6 -0.4 -61.0% -61.0% Total 769.8 739.2 +4.1% +4.4% 1 Adjusted information for the previous year (see consolidated statement of income). Revenue in the Drug Containment Solutions (DCS) segment was up 7.6% (at constant currencies: 9.2%), driven mainly by the change to the product mix as a result of the significant increase in demand for ready‑to‑use cartridges and vials, and the growth in special pharmaceutical vials. The vials have optimized inner surfaces, better geometric strength, and low-friction outer coatings, making them suitable for more demanding applications. Furthermore, the increased demand for core vials had a positive impact on revenue performance. Compared with the previous year, the Drug Delivery Systems (DDS) segment recorded a slight decline in revenue performance of -0.2% (at constant currencies: -1.7%). The buoyant demand for prefillable glass syringes, met in particular by the newly established manufacturing capacities in Hungary, had a positive impact. In contrast, the softer demand for polymer syringes in mRNA modalities weighed on revenue performance. Revenue performance by region (in EUR m) 9M 2026 9M 20251 Change in % EMEA 434.0 385.1 +12.7% Asia and South Pacific 121.7 127.6 -4.6% North America 145.8 161.3 -9.6% South America 68.4 65.3 +4.8% Total 769.8 739.2 +4.1% 1 Adjusted information for the previous year (see consolidated statement of income).
Page 5
SCHOTT Pharma Quarterly Statement as of June 30, 2026 Business performance and key financial indicators 5 EBITDA performance SCHOTT Pharma’s EBITDA was EUR 205.3m in the first nine months of the financial year 2026, and thus below the previous year’s figure of EUR 213.3m. The EBITDA margin was 26.7% compared with 28.9% in the same period in the previous year. (in EUR m) 9M 2026 9M 20251 Change in % Drug Containment Solutions (DCS) 109.7 99.6 +10.1% Drug Delivery Systems (DDS) 95.7 114.4 -16.3% Consolidation/reconciliation -0.1 -0.7 +79.4% Total 205.3 213.3 -3.8% 1 Adjusted information for the previous year (see consolidated statement of income). EBITDA in the DCS segment increased at a slightly higher rate than revenue , thereby raising the EBITDA margin to 24.6% (9M 2025: 24.1%). Alongside volume effects, the improved product mix – driven by the increased demand for HVS products – had a particularly positive impact. The DDS segment reported a decline in EBITDA. The EBITDA margin was 29.5% (9M 2025: 35.1%), driven mainly by a required impairment of inventories in the high single -digit million range for glass syringes as well as additional costs associated with optimizing production infrastructure and processes. In addition, the decrease in demand for polymer syringes and the associated lower capacity utilization weighed on EBITDA . The positive revenue performance for glass syringes was only able to partially offset these effects. In the previous year, EBITDA was impacted by negative exchange rate effects. In contrast, exchange rate effects were slightly positive in the first nine months of the current financial year. Exchange rate effects recognized in profit or loss are reported under the consolidation/reconciliation item. The Group’s cost of sales increased by 9.6%, outpacing the growth in revenue. The gross profit margin was 31.3% (9M 2025: 34.7%). The decline is mainly due to the aforementioned impairment for glass syringes, additional costs associated with optimizing production infrastructure and processes, as well as lower capacity utilization for polymer syringes. The balance of other operating income and expenses at EUR 7.5m was below the level in the previous year (9M 2025: EUR 8.5m), mainly due to the year-on-year decrease in income from recharged costs of EUR 3.6m. This mainly includes income from research and development projects carried out for customers as well as from other services provided to SCHOTT Group companies. The decrease was offset by an improved exchange rate result of EUR 1.8m and income of EUR 1.6m from the refund of US tariffs paid in the previous year. The financial result was up EUR 3.4m to EUR -6.2m compared with 9M 2025, driven mainly by lower interest expenses from cash pool financing resulting from the optimization of the financing structure carried out in Q1 2026 through intra-group debt restructuring. Income tax expenses amounted to EUR -30.2m, a year-on-year decrease of EUR 2.6m. While profit before income taxes was down EUR 12.8m, the tax rate rose marginally from 22.4% to 22.6%, mainly due to a change in the country mix compared to the previous year – based on profit before income taxes. The aforementioned effects resulted in a decline in profit for the period of EUR 10.3m to EUR 103.4m. Earnings per share amounted to EUR 0.68 (9M 2025: EUR 0.75).
Page 6
SCHOTT Pharma Quarterly Statement as of June 30, 2026 Business performance and key financial indicators 6 Financial position (in EUR m) 9M 2026 9M 20251 Change Cash flows from operating activities 140.7 127.7 +13.0 Cash flows from investing activities -105.8 -93.9 -11.9 Cash flows from financing activities -33.6 -28.1 -5.5 1 Adjusted information for the previous year (see consolidated statement of cash flows). SCHOTT Pharma posted positive cash flows from operating activities of EUR 140.7m in the first nine months of the financial year 2026 (9M 2025: EUR 127.7m). This was primarily due to operating income (EBIT) of EUR 139.7m (9M 2025: EUR 156.0m) as well as non -cash effective depreciation, amortization and impairment of non -current assets of EUR 65.5m (9M 2025: EUR 57.3m). The increase in depreciation, amortization and impairment reflects the extensive capital expenditure in capacity expansions in recent financi al years. Please refer to the “Results of operations” section for details of the key drivers of EBIT performance. Changes in working capital led to cash outflows of EUR -37.6m (9M 2025: EUR -39.7m). The cash outflows were primarily due to the lower trade liabilities to third parties and to SCHOTT Group. As of the previous year’s reporting date, these liabilities included higher amounts related to capital expenditure in the fourth quarter, which were settled at the beginning of the current financial year. Moreover, the offsetting of customer advance payments and the resulting reduction in contract liabilities led to cas h outflows. The increased business volume in Q3 2026 also weighed on working capital. This was reflected particularly in higher trade receivables from third parties and a rise in contract assets. The decrease in inventories had a positive impact on the change in working capital and cash flows from operating activities. In addition, income tax payments of EUR 29.2m (9M 2025: EUR 43.5m) reduced cash flows from operating activities. The high cash outflows in the previous year were largely due to tax payments in Germany, relating mainly to the fiscal years 2022 and 2023. The balance of interest received and paid led to cash outflows of EUR -1.9m in the first nine months of the financial year 2026 (9M 2025: EUR -6.1m). The year -on-year decrease was due to the optimization of the financing structure through an intra-group debt restructuring. Cash flows from investing activities are broken down as follows: (in EUR m) 9M 2026 9M 20251 Change Cash flows from ongoing investing activities -81.8 -88.2 +6.4 Cash flows from investment of liquid assets -24.0 -5.7 -18.3 Cash flows from investing activities -105.8 -93.9 -11.9 1 Adjusted information for the previous year (see consolidated statement of cash flows). Cash flows from ongoing investing activities include cash inflows from disposals and cash outflows for capital expenditure on property, plant and equipment and intangible assets. The balance amounted to EUR -81.8m in the reporting period, slightly below th e level in the previous year. Capital expenditure was allocated to capacity expansion projects in both segments, particularly at the locations in Hungary and Switzerland. Cash flows from investment of liquid assets mainly comprise changes in financial receivables – SCHOTT Group, i.e. cash pool receivables vis-à-vis SCHOTT Group. These led to cash outflows of EUR -21.8m in the first nine months of the financial year 2026 (9M 2025: EUR -5.7m). The background to this was the investment of liquid assets as part of cash pool and treasury management at SCHOTT Group, driven mainly by the positive free cash flow of our Group companies in the US and Mexico. Cash flows from financing activities led to cash outflows of EUR -33.6m in the reporting period (9M 2025: EUR -28.1m). Significant cash outflows included dividend payments of EUR -27.1m (9M 2025: EUR -24.1m) to our limited liability shareholders and EUR -0.5m (9M 2025: EUR -0.5m) to non -controlling interests. Further cash outflows amounted to EUR -4.9m (9M 2025: EUR -7.1m) from the allocation to plan assets and EUR -2.9m (9M 2025: EUR -3.9m) from the repayment of lease liabilities. These outflows were offset by cash inflows of EUR 1.7m
Page 7
SCHOTT Pharma Quarterly Statement as of June 30, 2026 Business performance and key financial indicators 7 (9M 2025: EUR 7.5m) from the change s in financial liabilities – SCHOTT Group, relating primarily to cash pool liabilities vis-à-vis SCHOTT Group. All in all, the increase in cash and cash equivalents was EUR 1.3m – based on the position as of the reporting date of September 30, 2025. Taking into account changes due to foreign exchange rates of EUR 1.1m, cash and cash equivalents amounted to EUR 24.9m as of June 30, 2026. Net assets Non-current assets Non-current assets were up EUR 55.7m to EUR 972.9m compared with September 30, 2025. This increase was mainly due to the EUR 48.0m increase in intangible assets and property, plant and equipment. Capital expenditure of EUR 83.3m was offset by depreciation and amortization of EUR 65.5m and disposals of non -current assets of EUR 0.7m. In addition, exchange rate effects of EUR 30.1m and inflationary adjustments at our Argentinian subsidiary led to an increase of EUR 0.8m. Capital expenditure was attributable mainly to the SCHOTT Pharma companies in Hungary and Switzerland, and involved the expansion of manufacturing capacities in both segments. It included non-cash effective additions of EUR 0.8m for right-of-use assets related to leases. The positive performance of our joint ventures in India and Italy contributed to a EUR 7.4m increase in the carrying amount of investments accounted for using the equity method. Current assets Current assets were up EUR 40.1m compared with September 30, 2025, driven mainly by a EUR 24.8m increase in financial receivables – SCHOTT Group, largely due to the positive free cash flow of our Group companies in the US and Mexico. In addition, contract assets and trade receivables from third parties and SCHOTT Group rose by a total of EUR 17.8m as a result of the higher volume of business in Q3 2026. Equity SCHOTT Pharma's equity amounted to EUR 998.4m as of the reporting date (September 30, 2025: EUR 893.7m) and the equity ratio increased from 55.9% to 58.9%. The higher ratio was due to a rise in equity of EUR 104.6m and a simultaneous uptick in total assets of EUR 95.8m. At EUR 103.4m, profit for the period in the first nine months of the financial year was the main factor driving the increase in equity, as well as foreign currency translation effects of EUR 25.4m and actuarial gains of EUR 3.4m in connectio n with changes in the interest rates relevant to the measurement of pension provisions. This was offset by dividend payments of EUR -27.6m to our limited liability shareholders and non-controlling interests. Please refer to the relevant statements in this section for more details on the changes in total assets. Non-current liabilities Non-current liabilities declined by EUR 4.1m to EUR 246.9m, driven mainly by contract liabilities which were down EUR 4.5m to EUR 112.2m as a result of offsetting advance payments received from customers. Current liabilities Compared with September 30, 2025, current liabilities were down EUR 4.7m to EUR 449.2m. The main driver of this decrease was the reduction in trade liabilities to third parties and SCHOTT Group of EUR 26.2m. As of the previous year’s reporting date, these liabilities included higher amounts related to capital expenditure in the fourth quarter, which were settled at the beginning of the current financial year. This was offset by an increase of EUR 11.4m in financial liabilities – SCHOTT Group, due in particular to exchange rate fluctuations as of the reporting date as well as a marginal increase in the financing requirement of individual Group companies in connection with ongoing capacity expansion projects. In addition, accrued liabilities were up EUR 7.2m, due in particular to higher accruals for services not yet invoiced.
Page 8
SCHOTT Pharma Quarterly Statement as of June 30, 2026 Report on changed forecasts 8 Report on changed forecasts Based on the strong business performance in the first nine months of the financial year 2026, expectations for Q4 2026, and the agreement reached with a key customer for glass syringes, the Management Board has adjusted the forecast for the financial year 2026 as follows: Key financial performance indicator Adjusted forecast Financial year 2026 Initial forecast Financial year 2026 Basis Financial year 2025 Revenue growth at constant currencies between 5% and 6% between 2% and 5% EUR 986.2m EBITDA margin between 27% and 28% around 27% 28.4% Detailed information on the initial forecast for the financial year 2026 can be found in the combined management report in the annual report 2025, beginning on page 37. For the adjusted forecast, please refer to the ad-hoc release dated July 8, 2026. The risk and opportunity position has not changed significantly since March 31, 2026. Taking all planned or implemented measures into account, there were no identifiable risks at the time of reporting that would individually or collectively jeopardize SCHO TT Pharma's existence as a going concern. Detailed information on SCHOTT Pharma’s risk management system and the risk and opportunity position can be found in the combined management report in the annual report 2025 beginning on page 39, and on page 10 of the half -year financial report 2026. Our forecast is based on various assumptions. In terms of revenue growth, it excludes portfolio measures but assumes that exchange rates will remain constant. Furthermore, it assumes that the geopolitical and global economic situation, global supply chains , inflation and energy supply will not deteriorate, and that there will be no further relevant pandemic-related restrictions or military conflicts. SCHOTT Pharma's actual performance may deviate positively or negatively from our forecast, either due to the risks and opportunities described in the annual report 2025 (chapter “Report on risks and opportunities” in the combined management report) and in the half -year financial report 2026 ( chapter “Report on risks and opportunities ”), or because our expectations and assumptions fail to materialize. Mainz, August 10, 2026 SCHOTT Pharma AG & Co. KGaA Represented by the Management Board of SCHOTT Pharma Management AG Dr. Christian Mias Reinhard Mayer
Page 9
SCHOTT Pharma Quarterly Statement as of June 30, 2026 Consolidated statement of income 9 Consolidated statement of income for the period from October 1, 2025 to June 30, 2026 (in EUR k) Q3 2026 Q3 20251 9M 2026 9M 20251 Revenue 281,760 256,178 769,828 739,233 Cost of sales -195,377 -160,230 -528,598 -482,444 Gross profit 86,383 95,948 241,230 256,789 Selling expenses -22,641 -20,653 -64,745 -63,303 General administrative expenses -12,655 -11,592 -36,791 -34,431 Research and development costs -6,340 -7,325 -19,728 -21,562 Other operating income 4,220 2,586 11,473 13,947 Other operating expenses -64 1,007 -3,942 -5,432 Share of profit from investments accounted for using the equity method 4,356 3,120 12,244 9,951 Operating income (EBIT) 53,259 63,091 139,741 155,959 Interest income 1,956 1,801 6,131 5,927 Interest expenses -3,869 -4,914 -11,879 -14,550 Net other financial result -116 10 -407 -938 Financial result -2,029 -3,103 -6,155 -9,561 Profit before income taxes 51,230 59,988 133,586 146,398 Income tax expenses -12,249 -14,396 -30,185 -32,736 Profit for the period 38,981 45,592 103,401 113,662 thereof attributable to non-controlling interests 153 163 380 407 thereof attributable to limited liability shareholders of SCHOTT Pharma KGaA 38,828 45,429 103,021 113,255 Earnings per share (in EUR), based on the share of profit for the period attributable to limited liability shareholders of SCHOTT Pharma KGaA Basic 0.26 0.30 0.68 0.75 Diluted 0.26 0.30 0.68 0.75 1 Adjusted information for the previous year – retrospective adjustment of revenue, cost of sales and income tax expenses as certain products were included in revenue recognized over time, although the requirements in accordance with IFRS 15.35(c) were not met in full. In the reporting period 9M 2025, revenue was up EUR 606k, cost of sales EUR -199k, and income tax expenses EUR -51k. In Q3 2025, revenue was down EUR -282k, cost of sales EUR 131k, and income tax expenses EUR 16k. Additional details are provided in note 3.5 of the notes to the consolidated financial statements in the annual report 2025.
Page 10
SCHOTT Pharma Quarterly Statement as of June 30, 2026 Consolidated statement of financial position 10 Consolidated statement of financial position as of June 30, 2026 Assets (in EUR k) Jun. 30, 2026 Sep. 30, 2025 Intangible assets 30,860 29,689 Property, plant and equipment 832,508 785,673 Investments accounted for using the equity method 95,942 88,498 Deferred tax assets 13,508 13,042 Other financial assets 25 1 Other non-financial assets 86 342 Non-current assets 972,929 917,245 Inventories 171,858 174,975 Contract assets 84,902 79,746 Trade receivables 208,832 195,263 Trade receivables – SCHOTT Group 5,152 6,095 Financial receivables – SCHOTT Group 179,876 155,103 Income tax assets 7,385 10,458 Other financial assets 14,955 11,396 Other non-financial assets 23,682 25,895 Cash and cash equivalents 24,877 22,470 Current assets 721,519 681,401 Total assets 1,694,448 1,598,646
Page 11
SCHOTT Pharma Quarterly Statement as of June 30, 2026 Consolidated statement of financial position 11 Consolidated statement of financial position Equity and liabilities (in EUR k) Jun. 30, 2026 Sep. 30, 2025 Subscribed capital 150,615 150,615 Capital reserves 494,481 494,481 Retained earnings 359,141 279,787 Other reserves -8,091 -33,100 Equity attributable to limited liability shareholders of SCHOTT Pharma KGaA 996,146 891,783 Non-controlling interests 2,205 1,966 Equity 998,351 893,749 Provisions for pensions and similar commitments 20,405 23,573 Provisions for income taxes 9,143 2,902 Other provisions 6,262 6,656 Deferred tax liabilities 22,013 21,989 Contract liabilities 112,188 116,700 Other financial liabilities 76,926 79,226 Non-current liabilities 246,937 251,046 Other provisions 12,572 9,917 Accrued liabilities 56,318 49,076 Contract liabilities 28,065 26,314 Trade liabilities 51,101 73,305 Trade liabilities – SCHOTT Group 26,622 30,574 Financial liabilities – SCHOTT Group 231,331 219,953 Income tax liabilities 15,739 22,498 Other financial liabilities 9,659 6,371 Other non-financial liabilities 17,753 15,843 Current liabilities 449,160 453,851 Total equity and liabilities 1,694,448 1,598,646
Page 12
SCHOTT Pharma Quarterly Statement as of June 30, 2026 Consolidated statement of cash flows 12 Consolidated statement of cash flows for the period from October 1, 2025 to June 30, 2026 (in EUR k) 9M 2026 9M 20251,2 Profit for the period 103,401 113,662 Depreciation, amortization and impairment as well as impairment reversals on non -current assets 65,511 57,346 Changes in provisions and accrued liabilities 20,181 10,395 Other non-cash income/expenses -13,993 -6,131 Net gain or loss on the disposal of intangible assets and property, plant and equipment -72 -243 Net gain or loss from financial assets -281 -774 Changes in inventories and advance payments made on inventories 10,295 -27,636 Changes in contract assets -5,156 -38,470 Changes in trade receivables -7,644 -85 Changes in trade receivables – SCHOTT Group 1,429 1,279 Changes in other assets 7,791 8,306 Changes in contract liabilities -8,073 42,294 Changes in trade liabilities -23,761 -17,580 Changes in trade liabilities – SCHOTT Group -4,702 539 Changes in other liabilities -3,000 -17,944 Changes in deferred taxes -1,199 2,773 Cash flows from operating activities (A) 140,727 127,731 Cash inflows from the sale of property, plant and equipment 727 1,135 Purchase of property, plant and equipment -82,346 -88,933 Purchase of intangible assets -179 -366 Cash flows from ongoing investing activities -81,798 -88,164 Cash inflows from the sale of financial assets 3,187 2,601 Purchase of financial assets -5,395 -2,601 Changes in financial receivables – SCHOTT Group -21,760 -5,739 Cash flows from investing activities (B) -105,766 -93,903 Dividends paid to limited liability shareholders -27,111 -24,098 Dividends paid to non-controlling interests -464 -479 Changes in financial liabilities – SCHOTT Group 1,720 7,455 Cash outflows from allocation to plan assets -4,899 -7,094 Cash outflows from repayments of outstanding lease liabilities -2,868 -3,862 Cash flows from financing activities (C) -33,622 -28,078
Page 13
SCHOTT Pharma Quarterly Statement as of June 30, 2026 Consolidated statement of cash flows 13 Consolidated statement of cash flows (in EUR k) 9M 2026 9M 2025 Net change in cash and cash equivalents (A+B+C) 1,339 5,750 Cash and cash equivalents at beginning of the period 22,470 23,182 - Cash on hand 1 3 - Bank deposits 22,469 23,179 Change in cash and cash equivalents due to foreign exchange rates 1,068 -644 Cash and cash equivalents at end of the period 24,877 28,288 - Cash on hand 3 3 - Bank deposits 24,874 28,285 Additional notes to the consolidated statement of cash flows 3 Interest paid -7,984 -12,005 Interest received 6,095 5,927 Income taxes paid -29,173 -43,544 1 Adjusted information for the previous year – retrospective adjustment within cash flows from operating activities as certain products were included in revenue recognized over time, although the requirements in accordance with IFRS 15.35(c) were not met in full. This resulted in reclassifications between individual line items without this having an impact on the total cash flows from operating activities. Additional details are provided in note 3.5 of the notes to the consolidated financial statements in the annual report 2025. 2 Adjusted information for the previous year – reclassifications from cash flows from financing activities: the item change in financial receivables – SCHOTT Group has been reported within cash flows from investing activities since the financial year 2025. Previously, allocation to cash flows from financing activities was based on an economic perspective (deviating from the provisions of IAS 7.16). A legal approach as set out in IAS 32.42 will be applied going forward. As a result, cash flows from investing activities were down EUR -5,739k. In addition, cash flows related to financial assets and financial liabilities have been r eclassified and from this point forward will be allocated to cash flows from operating activities. This led to an increase in cash flows from operating activities of EUR 148k. Cash flows from financing activities increased by a total of EUR 5,591k. Additional details are provided in note 33 of the notes to the consolidated financial statements in the annual report 2025. 3 Included in cash flows from operating activities.
Page 14
SCHOTT Pharma Quarterly Statement as of June 30, 2026 Supplementary information 14 Supplementary information Financial calendar Date Event December 10, 2026 Publication of annual report 2026 March 3, 2027 Annual General Meeting Disclaimer This quarterly statement contains forward -looking statements which are based on the Company's assumptions, expectations and intentions. Such statements are indicated by words such as “expect”, “assume”, “intend” or similar wording, and are based both on the information currently a vailable to management and on the prevailing environment. These may change at any time. The Company assumes no liability for the correctness and accuracy of any expectations or assumptions expressed in this statement. The Company also undertakes no obligat ion to update any of its forward -looking statements to bring them in line with actual developments after this quarterly statement has been published. Due to rounding, individual figures in this document and in other documents may not correspond exactly to the totals stated and percentages shown may not exactly reflect the absolute values to which they relate. Publication This quarterly statement was published on August 12, 2026. The document is also available in German. In the event of any discrepancies, the German version shall be authoritative. Translation: LanguageWire GmbH, Hamburg, Germany Photography: SCHOTT AG Imprint and contact SCHOTT Pharma AG & Co. KGaA Hattenbergstraße 10 55122 Mainz, Germany Tobias Erfurth Head of Investor Relations Website: www.schott-pharma.com Email: ir.pharma@schott.com